<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03601338</url>
  </required_header>
  <id_info>
    <org_study_id>HawlerMU2.7</org_study_id>
    <nct_id>NCT03601338</nct_id>
  </id_info>
  <brief_title>Low Molecular Weight Heparin in Pregnancies With Unexplained Stillbirths</brief_title>
  <official_title>Second Generation Low Molecular Weight Heparin (Bemiparin) as a Prophylactic for Management of Subsequent Pregnancy After an Unexplained Stillbirth: A Clinical Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hawler Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hawler Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bemiparin for pregnant women with abnormal umbilical artery Doppler ultrasound
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      152 women with history of unexplained stillbirths were identified , umbilical arty Doppler
      ultrasound was conducted for them at 20-22 weeks gestation . they were divided into two group
      , group one are those with abnormal resistant index (= or more than 0.6) thy received
      Bemiparin 2500 IU subcutaneously daily up to 24 hours before delivery .

      Group 2 with normal umbilical artery resistant index received no any interventions just
      routine antenatal follow up .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2015</start_date>
  <completion_date type="Actual">December 6, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>pregnant women with history of unexplained fetal death</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stillbirth</measure>
    <time_frame>after 20 weeks gestation to the delivery of fetus</time_frame>
    <description>Intrauterine fetal death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early neonatal death</measure>
    <time_frame>First week of life</time_frame>
    <description>Death of newborn</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low birth weight</measure>
    <time_frame>first hour of life</time_frame>
    <description>New borne with birth weight less than 5th percentile in kilogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm labor</measure>
    <time_frame>20-37 weeks</time_frame>
    <description>delivery of the fetus before 37 weeks gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-eclampsia</measure>
    <time_frame>20-41 week gestation</time_frame>
    <description>High blood pressure with protein urea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major abruptio placenta</measure>
    <time_frame>20-41 week gestation</time_frame>
    <description>Antepartum hemorrhage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Unexplained Stillbirth</condition>
  <arm_group>
    <arm_group_label>Bemiparin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women with high resistant index of umbilical artery received the intervention Bemiparin Sodium 2,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringe provided for each woman . The injections were received daily since 20 weeks gestation and up to 24 hours before delivery
Other Name: Hibor; Laboratories Rovi pharmaceuticals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal umbilical arty resistant index group received only multivitamins and routine antenatal follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bemiparin</intervention_name>
    <description>second generation low molecular weight Heparin</description>
    <arm_group_label>Bemiparin group</arm_group_label>
    <other_name>Hibor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>multivitamins and routine antenatal follow up</intervention_name>
    <description>multivitamins and routine antenatal follow up</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Second pregnancy after previous unexplained fetal death

          -  Singleton pregnancy

          -  No any medical disorders during pregnancy like diabetes or Systemic Lupus
             Erythematosus

          -  Normally located placenta

          -  No congenital fetal anomalies

          -  Patient accept to participate

        Exclusion Criteria:

          -  Confirmed thrombophilia

          -  Twin pregnancies

          -  Refused to participate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shahla k. Alalaf, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hawler Medical University, college of Medicine, department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ariana K. Jawad, CABOG</last_name>
    <role>Study Director</role>
    <affiliation>Kurdistan Board for Medical Specialist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahabad S. Ali, Diploma</last_name>
    <role>Study Chair</role>
    <affiliation>Maternity Teaching Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hawler Medical University</name>
      <address>
        <city>Erbil</city>
        <state>Kurdistan Region</state>
        <zip>44001</zip>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>December 7, 2018</last_update_submitted>
  <last_update_submitted_qc>December 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hawler Medical University</investigator_affiliation>
    <investigator_full_name>Shahla Alalaf</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Unexplained stillbirth</keyword>
  <keyword>Low molecular Weight Heparin</keyword>
  <keyword>Umbilical artery</keyword>
  <keyword>Doppler Ultrasound</keyword>
  <keyword>Antenatal care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stillbirth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bemiparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

